This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viatris Q1 Earnings Release: What's in Store for the Stock?
by Zacks Equity Research
VTRS' Q1 results are likely to gain from new product launches in all major geographies.
Should You Buy, Sell, or Hold FMS Stock Before Q1 Earnings?
by Zacks Equity Research
Fresenius Medical Care heads into the first quarter of 2025 with momentum from cost savings, innovation like the 5008X launch, and a steady recovery in U.S. treatment volumes.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
by Zacks Equity Research
CYH continues to witness growth in same-store admissions in the first quarter. Net loss per share is expected between 55 cents and breakeven in 2025.
Universal Health Q1 Earnings Beat on Strong Acute Care Admissions
by Zacks Equity Research
UHS continues to witness growth in acute care facilities' patient days, while behavioral health care services witness decline.
NeoGenomics (NEO) Reports Break-Even Earnings for Q1
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 100% and 1.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
by Zacks Equity Research
GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.
Here's How Charles River is Placed Just Ahead of Q1 Earnings
by Zacks Equity Research
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
by Zacks Equity Research
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
3 Reasons Growth Investors Will Love ANI (ANIP)
by Zacks Equity Research
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
by Zacks Equity Research
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
by Zacks Equity Research
MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
Zacks.com featured highlights include Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI
by Zacks Equity Research
Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI are part of the Zacks Screen of the Week article.
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
by Zacks Equity Research
VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Zacks.com featured highlights include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon
by Zacks Equity Research
ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon are part of the Zacks Screen of the Week article.
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.
5 Stocks With Recent Price Strength Amid Tariff-Led Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are HRTG, MRX, KINS, ANIP, HCI.
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like ANIP, HRTG, AVA and EXC are seeing price strength and the momentum is likely to continue.
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies
by Zacks Equity Research
Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.